You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Unresectable Advanced Renal Cell Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Renal Cell Carcinoma Trial in Beijing, Seoul (RO7247669, Tiragolumab, Pembrolizumab)

Recruiting
  • Renal Cell Carcinoma
  • Beijing, China
  • +1 more
Mar 28, 2023

Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma Trial in Auchenflower (RC198 Injection)

Not yet recruiting
  • Melanoma
  • +5 more
  • RC198 Injection
  • Auchenflower, Queensland, Australia
    Research Site
May 17, 2023

Advanced Clear Cell Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Renal Cell Carcinoma Trial in Duarte

Recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +11 more
  • Cabozantinib S-malate
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Duarte (Clostridium

Active, not recruiting
  • Advanced Renal Cell Carcinoma
  • +5 more
  • Clostridium butyricum CBM 588 Probiotic Strain
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Oct 12, 2022

Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) Trial ([68Ga]Ga-DPI-4452,

Not yet recruiting
  • Clear Cell Renal Cell Cancer (ccRCC)
  • +2 more
  • (no location specified)
Jan 20, 2023

Unresectable, Locally Advanced Or Metastatic Renal Cell

Completed
  • Locally Advanced or Metastatic Renal Cell Carcinoma
  • Cabozantinib monotherapy
  • All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
  • The Woodlands, Texas
    McKesson Life Sciences
Nov 11, 2021

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Not yet recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +31 more
  • Diagnostic Laboratory Biomarker Analysis
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +129 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Apr 8, 2022

Kidney Cancer, Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma Trial in United States (Talazoparib, Axitinib)

Recruiting
  • Kidney Cancer
  • +3 more
  • Basking Ridge, New Jersey
  • +6 more
Aug 8, 2022

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +41 more
  • Ipilimumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 11, 2022

Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma Trial in

Recruiting
  • Advanced Bladder Urothelial Carcinoma
  • +23 more
  • Riverside, California
  • +8 more
Jul 16, 2022

Advanced Solid Tumor, Unresectable Solid Tumor, Melanoma Trial in Australia, Canada, United States (MDNA11 Monotherapy, MDNA11

Recruiting
  • Advanced Solid Tumor
  • +24 more
  • MDNA11 Monotherapy
  • MDNA11 in combination with checkpoint inhibitor
  • Santa Monica, California
  • +7 more
Nov 1, 2022

Locally Advanced or Metastatic Renal Cell Carcinoma Trial in Worldwide (Cabozantinib)

Active, not recruiting
  • Locally Advanced or Metastatic Renal Cell Carcinoma
  • Salzburg, Austria
  • +39 more
Jan 18, 2023

Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral

Recruiting
  • Locally Advanced Renal Pelvis Urothelial Carcinoma
  • +20 more
  • Duarte, California
  • +16 more
Aug 10, 2022

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Metastatic Renal Cell Carcinoma Trial in Milan (Cabometyx)

Completed
  • Metastatic Renal Cell Carcinoma
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale Tumori
Apr 23, 2021

Advanced Malignant Solid Tumor, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +28 more
  • Conroe, Texas
  • +4 more
Dec 5, 2022

Renal Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer, Urothelial Carcinoma Trial in United States (XL092,

Recruiting
  • Renal Cell Carcinoma
  • +3 more
  • Tucson, Arizona
  • +3 more
Mar 30, 2022

RCC, Renal Cell Carcinoma Trial in Dallas (Cabozantinib 80 MG, Cabozantinib 40Mg Tab, Nivolumab)

Not yet recruiting
  • RCC
  • Renal Cell Carcinoma
  • Cabozantinib 80 MG
  • +2 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jul 3, 2023

Metastatic Renal Cell Carcinoma Trial in Worldwide (Ipilimumab plus nivolumab, Standard Therapy)

Recruiting
  • Metastatic Renal Cell Carcinoma
  • Ipilimumab plus nivolumab
  • Standard Therapy
  • Gent, Belgium
  • +40 more
Feb 7, 2022

Renal Cell Carcinoma Trial (Cabozantinib, Ipilimumab, Nivolumab)

Not yet recruiting
  • Renal Cell Carcinoma
  • (no location specified)
Jun 9, 2022

Carcinoma, Carcinoma, Renal Cell, Kidney Tumors Trial in Worldwide (Savolitinib, Sunitinib)

Active, not recruiting
Has Results
  • Carcinoma
  • +7 more
  • La Jolla, California
  • +58 more
Jan 13, 2023

Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,

Not yet recruiting
  • Bladder Squamous Cell Carcinoma
  • +10 more
  • Biospecimen Collection
  • +5 more
  • Atlanta, Georgia
  • +3 more
Feb 20, 2023

ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer Trial (NKT2152, palbociclib, sasanlimab)

Not yet recruiting
  • ccRCC
  • +20 more
  • (no location specified)
Jul 6, 2023

Advanced Renal Cell Carcinoma Trial in Beijing (ST-1898 tablets)

Recruiting
  • Advanced Renal Cell Carcinoma
  • ST-1898 tablets
  • Beijing, Beijing, China
    Peking University Cancer Hospital & Institute
Nov 6, 2023